Cardalis

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

benazepril hydrochloride, spironolactone

Available from:

Ceva Santé Animale

ATC code:

QC09BA07

INN (International Name):

benazepril hydrochloride, spironolactone

Therapeutic group:

Psi

Therapeutic area:

SRČNO-ŽILNI SISTEM

Therapeutic indications:

Za zdravljenje kongestivnega srčnega popuščanja, ki ga povzroča kronična degenerativna bolezen valvularov pri psih (z ustrezno diuretično podporo).

Product summary:

Revision: 4

Authorization status:

Pooblaščeni

Authorization date:

2012-07-23

Patient Information leaflet

                                16
B. NAVODILO ZA UPORABO
17
NAVODILO ZA UPORABO
Cardalis 2,5 mg/20 mg žvečljive tablete za pse
Cardalis 5 mg/40 mg žvečljive tablete za pse
Cardalis 10 mg/80 mg žvečljive tablete za pse
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ, ČE STA
RAZLIČNA
Imetnik dovoljenja za promet z zdravilom:
Ceva Santé Animale
10, av. de la Ballastière
33500 Libourne
Francija
Proizvajalec, odgovoren za sproščanje serij:
Ceva Santé Animale
Z.I. Tres le Bois
22600 Loudeac
Francija
Catalent Germany Schorndorf GmbH
Steinbeisstrasse 2
D-73614 Schorndorf
Nemčija
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Cardalis 2,5 mg/20 mg žvečljive tablete za pse
Benazeprilijev klorid 2,5 mg, spironolakton 20 mg
Cardalis 5 mg/40 mg žvečljive tablete za pse
Benazeprilijev klorid 5 mg, spironolakton 40 mg
Cardalis 10 mg/80 mg žvečljive tablete za pse
Benazeprilijev klorid 10 mg, spironolakton 80 mg
3.
NAVEDBA UČINKOVIN IN DRUGIH SESTAVIN
Vsaka žvečljiva tableta vsebuje:
BENAZEPRILIJEV KLORID
(HCL) (benazeprilium
HCl)
SPIRONOLAKTON
(spironolactonum)
Cardalis 2,5 mg/20 mg tablete
2,5 mg
20 mg
Cardalis 5 mg/40 mg tablete
5 mg
40 mg
Cardalis 10 mg/80 mg tablete
10 mg
80 mg
Tablete so rjave, okusne, ovalne oblike, z zarezo in žvečljive.
18
4.
INDIKACIJA(E)
Zdravljenje kongestivnega srčnega popuščanja zaradi kronične
degenerativne bolezni zaklopk pri psih
(z diuretično podporo, če je to potrebno).
5.
KONTRAINDIKACIJE
Ne uporabite v obdobju brejosti in laktacije (glej poglavje ''Brejost
in laktacija'').
Ne uporabite pri psih, ki se jih uporablja ali so namenjeni za vzrejo.
Ne uporabite pri psih s hipoadrenokorticizmom, hiperkaliemijo ali
hiponatriemijo.
Ne uporabite skupaj z nesteroidnimi protivnetnimi zdravili (NSAID) pri
psih z insuficienco ledvic.
Ne uporabite v primeru preobčutljivosti na zaviralce angiotenzin
konvertirajočega encima (zaviralci
ACE) ali na katerokoli pomožno snov.
Ne uporabite v primeru srčnega popuščanja zaradi aortne ali
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Cardalis 2,5 mg/20 mg žvečljive tablete za pse
Cardalis 5 mg/40 mg žvečljive tablete za pse
Cardalis 10 mg/80 mg žvečljive tablete za pse
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Vsaka žvečljiva tableta vsebuje:
UČINKOVINE:
BENAZEPRILIJEV KLORID
(HCL) (benazeprilum
HCl)
SPIRONOLAKTON
(spironolactonum)
Cardalis 2,5 mg/20 mg tablete
2,5 mg
20 mg
Cardalis 5 mg/40 mg tablete
5 mg
40 mg
Cardalis 10 mg/80 mg tablete
10 mg
80 mg
Pomožne snovi:
Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Žvečljive tablete.
Rjave okusne ovalne žvečljive tablete z zarezo.
Tablete lahko razpolovimo na dva enaka dela.
4.
KLINIČNI PODATKI
4.1
CILJNE ŽIVALSKE VRSTE
Psi.
4.2
INDIKACIJE ZA UPORABO PRI CILJNIH ŽIVALSKIH VRSTAH
Zdravljenje kongestivnega srčnega popuščanja zaradi kronične
degenerativne bolezni zaklopk pri psih
(z diuretično podporo, če je to potrebno).
4.3
KONTRAINDIKACIJE
Ne uporabite v obdobju brejosti in laktacije (glej poglavje 4.7).
Ne uporabite pri psih, ki se jih uporablja ali so namenjeni za vzrejo.
Ne uporabite pri psih s hipoadrenokorticizmom, hiperkaliemijo ali
hiponatriemijo.
Ne uporabite skupaj z nesteroidnimi protivnetnimi zdravili (NSAID) pri
psih z insuficienco ledvic.
Ne uporabite v primerih preobčutljivosti na zaviralce angiotenzin
konvertirajočega encima (zaviralci
ACE) ali na katerokoli pomožno snov.
Ne uporabite v primeru srčnega popuščanja zaradi aortne ali
pulmonarne stenoze.
4.4
POSEBNA OPOZORILA ZA VSAKO CILJNO ŽIVALSKO VRSTO
Jih ni.
3
4.5
POSEBNI PREVIDNOSTNI UKREPI
Posebni previdnostni ukrepi za uporabo pri živalih
Pred začetkom zdravljenja s benazeprilom in spironolaktonom, je
potrebno oceniti delovanje ledvic in
nivo serumskega kalija, še posebno pri psih, ki so lahko oboleli za
hipoadrenokorticizmom, hiperkaliemijo
ali hiponatriemijo. V nasprotju z ljudmi, pri kliničnih preizkusih s
to kombinacijo ni bilo opaziti
povečanega pojava hipe
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-11-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-11-2021
Public Assessment Report Public Assessment Report Bulgarian 17-06-2013
Patient Information leaflet Patient Information leaflet Spanish 04-11-2021
Public Assessment Report Public Assessment Report Spanish 17-06-2013
Patient Information leaflet Patient Information leaflet Czech 04-11-2021
Public Assessment Report Public Assessment Report Czech 17-06-2013
Patient Information leaflet Patient Information leaflet Danish 04-11-2021
Public Assessment Report Public Assessment Report Danish 17-06-2013
Patient Information leaflet Patient Information leaflet German 04-11-2021
Public Assessment Report Public Assessment Report German 17-06-2013
Patient Information leaflet Patient Information leaflet Estonian 04-11-2021
Public Assessment Report Public Assessment Report Estonian 17-06-2013
Patient Information leaflet Patient Information leaflet Greek 04-11-2021
Public Assessment Report Public Assessment Report Greek 17-06-2013
Patient Information leaflet Patient Information leaflet English 04-11-2021
Public Assessment Report Public Assessment Report English 17-06-2013
Patient Information leaflet Patient Information leaflet French 04-11-2021
Public Assessment Report Public Assessment Report French 17-06-2013
Patient Information leaflet Patient Information leaflet Italian 04-11-2021
Public Assessment Report Public Assessment Report Italian 17-06-2013
Patient Information leaflet Patient Information leaflet Latvian 04-11-2021
Public Assessment Report Public Assessment Report Latvian 17-06-2013
Patient Information leaflet Patient Information leaflet Lithuanian 04-11-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-11-2021
Public Assessment Report Public Assessment Report Lithuanian 17-06-2013
Patient Information leaflet Patient Information leaflet Hungarian 04-11-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 04-11-2021
Public Assessment Report Public Assessment Report Hungarian 17-06-2013
Patient Information leaflet Patient Information leaflet Maltese 04-11-2021
Public Assessment Report Public Assessment Report Maltese 17-06-2013
Patient Information leaflet Patient Information leaflet Dutch 04-11-2021
Public Assessment Report Public Assessment Report Dutch 17-06-2013
Patient Information leaflet Patient Information leaflet Polish 04-11-2021
Public Assessment Report Public Assessment Report Polish 17-06-2013
Patient Information leaflet Patient Information leaflet Portuguese 04-11-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 04-11-2021
Public Assessment Report Public Assessment Report Portuguese 17-06-2013
Patient Information leaflet Patient Information leaflet Romanian 04-11-2021
Public Assessment Report Public Assessment Report Romanian 17-06-2013
Patient Information leaflet Patient Information leaflet Slovak 04-11-2021
Public Assessment Report Public Assessment Report Slovak 17-06-2013
Patient Information leaflet Patient Information leaflet Finnish 04-11-2021
Public Assessment Report Public Assessment Report Finnish 17-06-2013
Patient Information leaflet Patient Information leaflet Swedish 04-11-2021
Public Assessment Report Public Assessment Report Swedish 17-06-2013
Patient Information leaflet Patient Information leaflet Norwegian 04-11-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 04-11-2021
Patient Information leaflet Patient Information leaflet Icelandic 04-11-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 04-11-2021
Patient Information leaflet Patient Information leaflet Croatian 04-11-2021

View documents history